ClinicalTrials.gg
CompletedNCT01687296Updated Jun 20, 2018Results posted

Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma

A Phase 3 interventional study of fluticasone propionate inhalation solution and oral prednisone in Asthma, sponsored by GlaxoSmithKline. Completed at 11 sites in China. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2018-06-20.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
81st of 238
261 · median 93
Started
2012
with 22 others
Phase 3
61 of 262
6 open now
Registered
155th of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 81st largest by enrollment of the 238 interventional ones that give a count, is one of 23 that started in 2012, is one of 61 in phase 3, and was the 155th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is a multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with oral prednisone administered for 7 days to Chinese pediatric and adolescent subjects (aged 4 to 16 years) with an acute exacerbation of asthma

Read the detailed description

This is a multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate (FP) 1mg twice daily compared with oral prednisone administered for 7 days to Chinese pediatric and adolescent subjects (aged 4 to 16 years) with an acute exacerbation of asthma. This study is for supporting registration of FP Nebules treating Chinese pediatric and adolescent subjects (aged 4 to 16 years) with an acute exacerbation of asthma in China.

At least 250 subjects, aged 4-16 years old, diagnosed an acute exacerbation of asthma at presentation, are eligible to take part in the study if they meet the inclusion criteria. They are randomly assigned at the ratio 1:1 to one of the following treatment groups for 7 days: FP Nebules 2×0.5mg/2ml twice daily/Placebo tablets once daily; Or, Oral prednisone tablets once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / Placebo Nebules 2×2ml 0.9% saline twice daily. While all subjects are given Salbutamol Nebules / MDI for relief of symptoms. After randomization (visit 1), the following visits are on Day5 (visit 2) and Day8 (visit 3), and a follow-up phone call (visit4) will happen two weeks post treatment on Day 21 for collection of adverse events.

The primary endpoint is mean morning PEF on diary card over the treatment assessment period. The secondary endpoints include subject derived data (symptom scores ), evening PEF on diary card, use of rescue medications, clinic assessments of pulmonary function ( FEV1, and FVC) , clinical scoring index , patient/parent and investigator global evaluation, and use of rescue medications during the trial. Safety endpoints include AEs, vital signs, and oropharyngeal examinations, and laboratory tests (haematology, urinalysis, chemistry). The subjects are assessed for compliance on completion of diary card.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • PEF
  • inhaled
  • Fluticasone Propionate
  • safety
  • prednisone
  • acute exacerbation
  • asthma
  • efficacy
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese male and female pediatric or adolescent subjects aged 4 to 16 years, inclusive
  • Subjects have an established diagnosis of asthma
  • The definition of asthma. According to Chinese Guideline for the diagnosis and optimal management of asthma in children [Respiratory branch of pediatric society,Chinese Medical. Association. 2008, revised version], the subjects can be diagnosed when meeting the criteria. The diagnosis criteria is listed in the protocol.
  • The severity of an acute exacerbation of asthma is defined as PEF of 50% to 75% predicted via a peak flow meter, with a clinical scoring index of ≥2. The clinical scoring index represents the sum of the score for each of four signs: respiratory rate (0=low to 3=high, dependent on age), wheezing (0=none to 3=severe), inspiration/expiration ratio (0=2:1 to 3=1:3), and accessory muscle (0=none to 3=marked use).
  • Subjects can properly use a mini-wright peak flow meter, nebulizer and MDI with/without a spacer, and accurately complete a diary card with parental assistance, if required.
  • Subjects' parents/guardians are willing to give written .

Exclusion criteria

Exclusion criteria:

  • Severe respiratory dysfunction.
  • History of mechanical ventilation due to respiratory failure.
  • Admission to hospital due to respiratory disease within the previous 2 weeks, including asthmatic exacerbations.
  • Clinical or lab evidence of a serious, uncontrolled systemic disease or presence of any disease likely to interfere with the objectives of this study, such as pulmonary cystic fibrosis and bronchopulmonary dysplasia.
  • Known or suspected to glucocorticosteroids or β2 agonists.
  • Clinical visual evidence of oral candidiasis at Visit1.
  • Use of the medications below in Table 1 according to the following defined time intervals prior to presentation. The list is provided in the protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    fluticasone Nebules/placebo tablet

    2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily

    Drug: fluticasone propionate inhalation solution · Drug: placebo tablet · Drug: salbutamol

  • Active comparator
    oral prednisone/placebo inhalation solution

    once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily

    Drug: oral prednisone · Drug: placebo inhalation solution · Drug: salbutamol

Interventions

  • Drugfluticasone propionate inhalation solution

    2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days

  • once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days

  • Drugplacebo inhalation solution

    4ml 0.9% saline nebulized twice daily

  • Drugplacebo tablet

    placebo soluble tablet, oral ,once daily

  • Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.

06

What researchers measure

Primary outcomes

  1. Mean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population

    PEF is the maximum flow generated during a forceful exhalation, starting from full lung inflation. Participants (if needed with the help of parents or guardian) recorded on diary card the best of three PEF measurements, using a mini-Wright peak flow meter in the morning before taking any study drug. Only data that was drawn from Days 2 to 8 after randomization and on or before one day after the end date of study drug was used for analysis. The outcome measure was considered missing if less than 2 days were recorded in the given treatment assessment period. Two participants from fluticasone propionate group and 4 participants from prednisone group had the missing outcome measure. Analysis was performed using an analysis of covariance (ANCOVA) model with effects due to gender, age, centre and treatment group.

    Time frame: Days 2 to 8

  2. Mean Morning PEF on Diary Card Over the Treatment Assessment Period in Per Protocol (PP) Population

    PEF is the maximum flow generated during a forceful exhalation, starting from full lung inflation. Participants (if needed with the help of parents or guardian) recorded on diary card the best of three PEF measurements, using a mini-Wright peak flow meter in the morning before talking any study drug. Only data that was drawn from Days 2 to 8 after randomization and on or before one day after the end date of study drug was used for analysis. The outcome measure was considered missing if less than 2 days were recorded in the given treatment assessment period. Two participants from fluticasone propionate group and 5 participants from prednisone group had the missing outcome measure. Analysis was performed using ANCOVA model with effects due to gender, age ,centre and treatment group.

    Time frame: Days 2 to 8

Secondary outcomes

  1. Mean Evening PEF on Diary Card Over the Treatment Assessment Period

    PEF is the maximum flow generated during a forceful exhalation, starting from full lung inflation. Participants recorded on diary card the best of three PEF measurements, using a mini-Wright peak flow meter in the evening (6:00-9:00 post meridiem \[PM\]) before taking any study drug. Only data that was drawn from Days 1/2 to 8 after randomization and before or on the end date of study drug was used for analysis. If participants started to take the study drug in the morning (early or on 12:00 PM), only then the evening PEF on the date of randomization was used. The outcome measure was considered missing if less than 2 days was recorded in the given treatment assessment period. Two participants from fluticasone propionate group and 5 participants from prednisone group had the missing outcome measure. Analysis was performed using an ANCOVA model with effects due to gender, age, centre and treatment group.

    Time frame: Days 1/2 to 8

  2. Median Day-time and Night-time Symptom Scores Over the Treatment Assessment Period

    The symptoms of cough, sputum production, wheeze and dyspnoea were assessed in morning and evening, and recorded on participant diary cards. Day-time symptoms were scored while retiring to bed on a scale of 0 (no symptoms) to 5 (severe). Night-time symptoms were scored while waking in the morning on a scale of 0 (no symptoms) to 4 (severe). For day-time score, only data that was from Days 2 to 8 after randomization and before or on the end date of study drug was used. For night-time score, only data that are from Days 2 to 8 after randomization and on or before one day after the end date of study drug was used. The outcome measure was considered missing if less than 2 days were recorded in the given treatment assessment period. The analysis only includes participants with at least 2 days of non-missing symptom scores in the given treatment assessment period.

    Time frame: Days 2 to 8

  3. Median Number of Use of Rescue Medications During Day and Night Over the Treatment Assessment Period

    The use of nebulized salbutamol (doses/puffs and frequency) were recorded on diary card in the morning and evening. The median numbers of times of use of rescue medication during day and night was calculated for each participant over the treatment assessment period. In each case, only data that was from Days 2 to 8 after randomization and before or on the end date of study drug was used. The outcome measure was considered missing if less than 2 days (that is., 24-hour periods) were recorded in the given treatment assessment period. The analysis only includes participants who have at least 2 days of non-missing numbers of times rescue medication (including zero) in the given treatment assessment period.

    Time frame: Days 2 to 8

  4. Clinical Assessment of Lung Function of Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) During the Treatment Period

    Spirometric assessments of FEV1 and FVC were assessed at clinic visit 1 (Screening), 2 (Day 5) and 3 (Day 8). Lung function tests were performed at the approximately same time at each visit in the morning. Participants were instructed to withhold salbutamol therapy for at least 4 hour, and the highest of three FEV1 and FVC measurements were recorded. If participants discontinued before or on Day 5, then the FEV1 and FVC collected at the early withdrawal visit is included in the Visit 2. Otherwise, the FEV1, FVC collected at the early withdrawal visit was included in the Visit 3. Analysis was performed using ANCOVA with covariates of gender, centre, age and treatment.

    Time frame: During the treatment period at Day 5, Day 8

  5. Mean Change From Baseline in Clinical Scoring Index at Day 5 and Day 8

    The clinical scoring index was assessed at Baseline (Visit 1), Day 5 and Day 8. The score assigned represented the sum of the score for each of four signs: respiratory rate, wheezing, inspiration/expiration ratio, and accessory muscle use. Each of these parameters were scored on a 4-point scale of 0 to 3 where 0=none, 1=mild, 2=moderate and 3=severe. The total score ranged from 0 to 12, where 0 indicated absence of symptoms and 12 indicated most severe symptoms. The Baseline value was the last non-missing value prior to randomization. Change from Baseline was calculated/defined as value at the indicated visit minus value at the Baseline. A negative value of change in score from Baseline indicated improvement in severity of symptoms. If participants discontinued before or on Day 5, then the clinical scoring index collected at the early withdrawal visit was included in the Visit 2. Otherwise, the clinical scoring index collected at the early withdrawal visit was included in the Visit 3

    Time frame: Baseline, Day 5 and Day 8

  6. Mean Global Evaluation for Efficacy by Participant/Parent and Investigator

    At Visit 3 (Day 8), participant/parent and investigator were asked to evaluate efficacy globally as very beneficial=1, beneficial=2, no effect=3 or worse=4. The global evaluation collected at the early withdrawal visit was included in the Visit 3. If participants were discontinued at Visit 2, then the global evaluation collected at the Visit 2 is also included in the Visit 3 for summary and analysis.

    Time frame: Day 8

07

Results

Posted Jan 30, 2018

Participant flow

The study was planned on 250 Chinese paediatric and adolescent participants (aged 4 to 16 years) with an acute exacerbation of asthma and was conducted at 11 centres in China from 12th November 2012 to 21st June 2013.

Participant flow — Overall Study
MilestoneFluticasone PropionatePrednisone
Started123128
Completed116123
Not completed75
Withdrew: Lack of efficacy11
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject63

Outcome measures

PrimaryMean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population

PEF is the maximum flow generated during a forceful exhalation, starting from full lung inflation. Participants (if needed with the help of parents or guardian) recorded on diary card the best of three PEF measurements, using a mini-Wright peak flow meter in the morning before taking any study drug. Only data that was drawn from Days 2 to 8 after randomization and on or before one day after the end date of study drug was used for analysis. The outcome measure was considered missing if less than 2 days were recorded in the given treatment assessment period. Two participants from fluticasone propionate group and 4 participants from prednisone group had the missing outcome measure. Analysis was performed using an analysis of covariance (ANCOVA) model with effects due to gender, age, centre and treatment group.

Time frame:
Days 2 to 8
Reported as:
Least squares mean · Litres per minute (L/min)
Mean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population
Litres per minute (L/min)Fluticasone PropionatePrednisone
Mean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population188.77 ± 3.774188.31 ± 3.790
Statistical analysis
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.931 · Mean difference (final values): 0.46 · 95% CI -9.85 to 10.76
PrimaryMean Morning PEF on Diary Card Over the Treatment Assessment Period in Per Protocol (PP) Population

PEF is the maximum flow generated during a forceful exhalation, starting from full lung inflation. Participants (if needed with the help of parents or guardian) recorded on diary card the best of three PEF measurements, using a mini-Wright peak flow meter in the morning before talking any study drug. Only data that was drawn from Days 2 to 8 after randomization and on or before one day after the end date of study drug was used for analysis. The outcome measure was considered missing if less than 2 days were recorded in the given treatment assessment period. Two participants from fluticasone propionate group and 5 participants from prednisone group had the missing outcome measure. Analysis was performed using ANCOVA model with effects due to gender, age ,centre and treatment group.

Time frame:
Days 2 to 8
Reported as:
Least squares mean · L/min
Mean Morning PEF on Diary Card Over the Treatment Assessment Period in Per Protocol (PP) Population
L/minFluticasone PropionatePrednisone
Mean Morning PEF on Diary Card Over the Treatment Assessment Period in Per Protocol (PP) Population189.46 ± 3.724188.96 ± 3.712
Statistical analysis
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.922 · Mean difference (final values): 0.50 · 95% CI -9.64 to 10.65
SecondaryMean Evening PEF on Diary Card Over the Treatment Assessment Period

PEF is the maximum flow generated during a forceful exhalation, starting from full lung inflation. Participants recorded on diary card the best of three PEF measurements, using a mini-Wright peak flow meter in the evening (6:00-9:00 post meridiem \[PM\]) before taking any study drug. Only data that was drawn from Days 1/2 to 8 after randomization and before or on the end date of study drug was used for analysis. If participants started to take the study drug in the morning (early or on 12:00 PM), only then the evening PEF on the date of randomization was used. The outcome measure was considered missing if less than 2 days was recorded in the given treatment assessment period. Two participants from fluticasone propionate group and 5 participants from prednisone group had the missing outcome measure. Analysis was performed using an ANCOVA model with effects due to gender, age, centre and treatment group.

Time frame:
Days 1/2 to 8
Reported as:
Least squares mean · L/min
Mean Evening PEF on Diary Card Over the Treatment Assessment Period
L/minFluticasone PropionatePrednisone
Mean Evening PEF on Diary Card Over the Treatment Assessment Period195.79 ± 3.723194.63 ± 3.751
Statistical analysis
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.822 · Mean difference (final values): 1.16 · 95% CI -9.02 to 11.34
SecondaryMedian Day-time and Night-time Symptom Scores Over the Treatment Assessment Period

The symptoms of cough, sputum production, wheeze and dyspnoea were assessed in morning and evening, and recorded on participant diary cards. Day-time symptoms were scored while retiring to bed on a scale of 0 (no symptoms) to 5 (severe). Night-time symptoms were scored while waking in the morning on a scale of 0 (no symptoms) to 4 (severe). For day-time score, only data that was from Days 2 to 8 after randomization and before or on the end date of study drug was used. For night-time score, only data that are from Days 2 to 8 after randomization and on or before one day after the end date of study drug was used. The outcome measure was considered missing if less than 2 days were recorded in the given treatment assessment period. The analysis only includes participants with at least 2 days of non-missing symptom scores in the given treatment assessment period.

Time frame:
Days 2 to 8
Reported as:
Median · Scores on a scale
Median Day-time and Night-time Symptom Scores Over the Treatment Assessment Period
Scores on a scaleFluticasone PropionatePrednisone
Day-time symptom score0.5 (0 to 3)1.0 (0 to 3)
Night-time symptom score0.0 (0 to 3)0.0 (0 to 4)
Statistical analysis
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.717
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.683
SecondaryMedian Number of Use of Rescue Medications During Day and Night Over the Treatment Assessment Period

The use of nebulized salbutamol (doses/puffs and frequency) were recorded on diary card in the morning and evening. The median numbers of times of use of rescue medication during day and night was calculated for each participant over the treatment assessment period. In each case, only data that was from Days 2 to 8 after randomization and before or on the end date of study drug was used. The outcome measure was considered missing if less than 2 days (that is., 24-hour periods) were recorded in the given treatment assessment period. The analysis only includes participants who have at least 2 days of non-missing numbers of times rescue medication (including zero) in the given treatment assessment period.

Time frame:
Days 2 to 8
Reported as:
Median · Number of use of rescue medication
Median Number of Use of Rescue Medications During Day and Night Over the Treatment Assessment Period
Number of use of rescue medicationFluticasone PropionatePrednisone
Median Number of Use of Rescue Medications During Day and Night Over the Treatment Assessment Period2.0 (0 to 3)2.0 (0 to 3)
Statistical analysis
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.996
SecondaryClinical Assessment of Lung Function of Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) During the Treatment Period

Spirometric assessments of FEV1 and FVC were assessed at clinic visit 1 (Screening), 2 (Day 5) and 3 (Day 8). Lung function tests were performed at the approximately same time at each visit in the morning. Participants were instructed to withhold salbutamol therapy for at least 4 hour, and the highest of three FEV1 and FVC measurements were recorded. If participants discontinued before or on Day 5, then the FEV1 and FVC collected at the early withdrawal visit is included in the Visit 2. Otherwise, the FEV1, FVC collected at the early withdrawal visit was included in the Visit 3. Analysis was performed using ANCOVA with covariates of gender, centre, age and treatment.

Time frame:
During the treatment period at Day 5, Day 8
Reported as:
Least squares mean · Litres
Clinical Assessment of Lung Function of Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) During the Treatment Period
LitresFluticasone PropionatePrednisone
FEV1, Day 51.288 ± 0.03481.331 ± 0.0332
FEV1, Day 81.400 ± 0.02941.396 ± 0.0280
FVC, Day 51.476 ± 0.04541.543 ± 0.0439
FVC, Day 81.544 ± 0.03261.582 ± 0.0316
Statistical analysis
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.348 · Mean difference (final values): -0.044 · 95% CI -0.135 to 0.048
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.914 · Mean difference (final values): 0.004 · 95% CI -0.074 to 0.083
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.276 · Mean difference (final values): -0.067 · 95% CI -0.187 to 0.054
  • Fluticasone Propionate vs Prednisone · ANCOVA · p = 0.384 · Mean difference (final values): -0.039 · 95% CI -0.126 to 0.049
SecondaryMean Change From Baseline in Clinical Scoring Index at Day 5 and Day 8

The clinical scoring index was assessed at Baseline (Visit 1), Day 5 and Day 8. The score assigned represented the sum of the score for each of four signs: respiratory rate, wheezing, inspiration/expiration ratio, and accessory muscle use. Each of these parameters were scored on a 4-point scale of 0 to 3 where 0=none, 1=mild, 2=moderate and 3=severe. The total score ranged from 0 to 12, where 0 indicated absence of symptoms and 12 indicated most severe symptoms. The Baseline value was the last non-missing value prior to randomization. Change from Baseline was calculated/defined as value at the indicated visit minus value at the Baseline. A negative value of change in score from Baseline indicated improvement in severity of symptoms. If participants discontinued before or on Day 5, then the clinical scoring index collected at the early withdrawal visit was included in the Visit 2. Otherwise, the clinical scoring index collected at the early withdrawal visit was included in the Visit 3

Time frame:
Baseline, Day 5 and Day 8
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Clinical Scoring Index at Day 5 and Day 8
Scores on a scaleFluticasone PropionatePrednisone
Day 5-2.7 ± 1.41-2.6 ± 1.44
Day 8-3.4 ± 1.26-3.4 ± 1.26
Statistical analysis
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.507
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.700
SecondaryMean Global Evaluation for Efficacy by Participant/Parent and Investigator

At Visit 3 (Day 8), participant/parent and investigator were asked to evaluate efficacy globally as very beneficial=1, beneficial=2, no effect=3 or worse=4. The global evaluation collected at the early withdrawal visit was included in the Visit 3. If participants were discontinued at Visit 2, then the global evaluation collected at the Visit 2 is also included in the Visit 3 for summary and analysis.

Time frame:
Day 8
Reported as:
Mean · Scores on a scale
Mean Global Evaluation for Efficacy by Participant/Parent and Investigator
Scores on a scaleFluticasone PropionatePrednisone
Participant/parent global evaluation1.5 ± 0.591.5 ± 0.52
Investigator global evaluation1.5 ± 0.561.5 ± 0.52
Statistical analysis
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.633
  • Fluticasone Propionate vs Prednisone · Wilcoxon rank sum test · p = 0.323

Adverse events

Collected over On- treatment serious adverse events (SAE) and non- serious adverse events (AE) were collected from start of study medication through the treatment phase up to 8 days (only on-treatment events captured).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Propionate0/123 (0%)1/123 (0.8%)1/123 (0.8%)
Prednisone0/128 (0%)2/128 (1.6%)10/128 (7.8%)
Most frequent serious events
Most frequent serious events
EventFluticasone PropionatePrednisone
Upper respiratory tract infectionInfections and infestations1/1232/128
Most frequent other events
Most frequent other events
EventFluticasone PropionatePrednisone
White blood cell count increasedInvestigations1/12310/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone PropionatePrednisoneTotal
Mean6.6 ± 2.416.5 ± 2.326.5 ± 2.36
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone PropionatePrednisoneTotal
Female5151102
Male7277149
Region of Enrollment
Region of Enrollment(Participants)Fluticasone PropionatePrednisoneTotal
China123128251
08

Study locations

11 sites
  • GSK Investigational Site
    Changsha, Hunan 410005, China
  • GSK Investigational Site
    Yanji, Jilin 133000, China
  • GSK Investigational Site
    Shenyang, Liaoning 110004, China
  • GSK Investigational Site
    Wenzhou, Zhejiang 323027, China
  • GSK Investigational Site
    Beijing, 100191, China
  • GSK Investigational Site
    Beijing, China
  • GSK Investigational Site
    Changchun, China
  • GSK Investigational Site
    Chongqing, 400014, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200092, China
  • GSK Investigational Site
    Wuxi, 214023, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2012
First posted
Sep 18, 2012
Start
Nov 12, 2012
Primary completionActual
Jun 1, 2013
CompletionActual
Jun 21, 2013
Results first posted
Jan 30, 2018
Last update
Jun 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01687296
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Nov 12, 2012
Primary completion
Jun 1, 2013
Completion
Jun 21, 2013
Results posted
Jan 30, 2018
Last update
Jun 20, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion